B J Noordman1, M G E Verdam2, S M Lagarde3, J Shapiro3, M C C M Hulshof4, M I van Berge Henegouwen5, B P L Wijnhoven3, G A P Nieuwenhuijzen6, J J Bonenkamp7, M A Cuesta8, J Th M Plukker9, E J Spillenaar Bilgen10, E W Steyerberg11, A van der Gaast12, M A G Sprangers2, J J B van Lanschot3. 1. Department of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: b.noordman@erasmusmc.nl. 2. Department of Medical Psychology, Amsterdam, The Netherlands. 3. Department of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands. 4. Department of Radiation Oncology, Amsterdam, The Netherlands. 5. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. 6. Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands. 7. Department of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 8. Department of Surgery, VU Medical Center, Amsterdam, The Netherlands. 9. Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands. 10. Department of Surgery, Rijnstate Hospital, Arnhem, The Netherlands. 11. Department of Public Health, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands. 12. Department of Medical Oncology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard of care for patients with esophageal or junctional cancer, but the long-term impact of nCRT on health-related quality of life (HRQOL) is unknown. The purpose of this study is to compare very long-term HRQOL in long-term survivors of esophageal cancer who received nCRT plus surgery or surgery alone. Patients and methods: Patients were randomly assigned to receive nCRT (carboplatin/paclitaxel with 41.4-Gy radiotherapy) plus surgery or surgery alone. HRQOL was measured using EORTC-QLQ-C30, EORTC-QLQ-OES24 and K-BILD questionnaires after a minimum follow-up of 6 years. To allow for examination over time, EORTC-QLQ-C30 and QLQ-OES24 questionnaire scores were compared with pretreatment and 12 months postoperative questionnaire scores. Physical functioning (QLQ-C30), eating problems (QLQ-OES24) and respiratory problems (K-BILD) were predefined primary end points. Predefined secondary end points were global quality of life and fatigue (both QLQ-C30). Results: After a median follow-up of 105 months, 123/368 included patients (33%) were still alive (70 nCRT plus surgery, 53 surgery alone). No statistically significant or clinically relevant differential effects in HRQOL end points were found between both groups. Compared with 1-year postoperative levels, eating problems, physical functioning, global quality of life and fatigue remained at the same level in both groups. Compared with pretreatment levels, eating problems had improved (Cohen's d -0.37, P = 0.011) during long-term follow-up, whereas physical functioning and fatigue were not restored to pretreatment levels in both groups (Cohen's d -0.56 and 0.51, respectively, both P < 0.001). Conclusions: Although physical functioning and fatigue remain reduced after long-term follow-up, no adverse impact of nCRT is apparent on long-term HRQOL compared with patients who were treated with surgery alone. In addition to the earlier reported improvement in survival and the absence of impact on short-term HRQOL, these results support the view that nCRT according to CROSS can be considered as a standard of care. Trial registration number: Netherlands Trial Register NTR487.
RCT Entities:
Background: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard of care for patients with esophageal or junctional cancer, but the long-term impact of nCRT on health-related quality of life (HRQOL) is unknown. The purpose of this study is to compare very long-term HRQOL in long-term survivors of esophageal cancer who received nCRT plus surgery or surgery alone. Patients and methods: Patients were randomly assigned to receive nCRT (carboplatin/paclitaxel with 41.4-Gy radiotherapy) plus surgery or surgery alone. HRQOL was measured using EORTC-QLQ-C30, EORTC-QLQ-OES24 and K-BILD questionnaires after a minimum follow-up of 6 years. To allow for examination over time, EORTC-QLQ-C30 and QLQ-OES24 questionnaire scores were compared with pretreatment and 12 months postoperative questionnaire scores. Physical functioning (QLQ-C30), eating problems (QLQ-OES24) and respiratory problems (K-BILD) were predefined primary end points. Predefined secondary end points were global quality of life and fatigue (both QLQ-C30). Results: After a median follow-up of 105 months, 123/368 included patients (33%) were still alive (70 nCRT plus surgery, 53 surgery alone). No statistically significant or clinically relevant differential effects in HRQOL end points were found between both groups. Compared with 1-year postoperative levels, eating problems, physical functioning, global quality of life and fatigue remained at the same level in both groups. Compared with pretreatment levels, eating problems had improved (Cohen's d -0.37, P = 0.011) during long-term follow-up, whereas physical functioning and fatigue were not restored to pretreatment levels in both groups (Cohen's d -0.56 and 0.51, respectively, both P < 0.001). Conclusions: Although physical functioning and fatigue remain reduced after long-term follow-up, no adverse impact of nCRT is apparent on long-term HRQOL compared with patients who were treated with surgery alone. In addition to the earlier reported improvement in survival and the absence of impact on short-term HRQOL, these results support the view that nCRT according to CROSS can be considered as a standard of care. Trial registration number: Netherlands Trial Register NTR487.
Authors: Matthew Parsons; Shane Lloyd; Skyler Johnson; Courtney Scaife; Thomas Varghese; Robert Glasgow; Ignacio Garrido-Laguna; Randa Tao Journal: Ann Surg Oncol Date: 2020-07-09 Impact factor: 5.344
Authors: Richard A Malthaner; Edward Yu; Michael Sanatani; Debra Lewis; Andrew Warner; A Rashid Dar; Brian P Yaremko; Joel Bierer; David A Palma; Dalilah Fortin; Richard I Inculet; Eric Fréchette; Jacques Raphael; Stewart Gaede; Sara Kuruvilla; Jawaid Younus; Mark D Vincent; George B Rodrigues Journal: Thorac Cancer Date: 2022-05-24 Impact factor: 3.223
Authors: Berend Jan van der Wilk; Ben M Eyck; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot Journal: Dig Surg Date: 2018-09-18 Impact factor: 2.588
Authors: Kelly Chinh; Catherine E Mosher; Linda F Brown; Kathleen A Beck-Coon; Kurt Kroenke; Shelley A Johns Journal: Mindfulness (N Y) Date: 2020-01-14
Authors: E Jezerskyte; L M Saadeh; E R C Hagens; M A G Sprangers; L Noteboom; H W M van Laarhoven; W J Eshuis; M C C M Hulshof; M I van Berge Henegouwen; S S Gisbertz Journal: J Gastrointest Surg Date: 2020-09-09 Impact factor: 3.452
Authors: Maria J Valkema; Berend J van der Wilk; Ben M Eyck; Bas P L Wijnhoven; Manon C W Spaander; Michail Doukas; Sjoerd M Lagarde; Wendy M J Schreurs; Mark J Roef; J Jan B van Lanschot; Roelf Valkema Journal: J Nucl Med Date: 2020-09-04 Impact factor: 11.082